Fluorocyclopentenylcytosine - Rexahn Pharmaceuticals

Drug Profile

Fluorocyclopentenylcytosine - Rexahn Pharmaceuticals

Alternative Names: FCPEC; RX 3117

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Apoptosis stimulants; CDC2 protein kinase inhibitors; Cell division inhibitors; DNA cytosine 5 methyltransferase 1 inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Bladder cancer
  • Phase I Solid tumours

Most Recent Events

  • 13 Nov 2017 Phase I development is ongoing for Solid-tumours (Late-stage disease) in USA (PO, Capsule) (NCT02030067)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Hungary (PO, Capsule)
  • 10 Oct 2017 EMA's Committee for Orphan Medicinal Products recommends orphan drug designation for fluorocyclopentenylcytosine in the European Union for Pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top